Protocol for the CONVERT trial—Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status

INTRODUCTION: Concurrent ONce-daily VErsus twice-daily RadioTherapy (CONVERT) is the only multicentre, international, randomised, phase III trial open in Europe and Canada looking at optimisation of chemoradiotherapy (RT) in limited stage small cell lung cancer (LS-SCLC). Following on from the Turri...

Descripción completa

Detalles Bibliográficos
Autores principales: Faivre-Finn, Corinne, Falk, Sally, Ashcroft, Linda, Bewley, Michelle, Lorigan, Paul, Wilson, Elena, Groom, Nicki, Snee, Michael, Fournel, Pierre, Cardenal, Felipe, Bezjak, Andrea, Blackhall, Fiona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735219/
https://www.ncbi.nlm.nih.gov/pubmed/26792218
http://dx.doi.org/10.1136/bmjopen-2015-009849

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735219/
https://www.ncbi.nlm.nih.gov/pubmed/26792218
http://dx.doi.org/10.1136/bmjopen-2015-009849

Ejemplares similares